IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
S.F. Holding 06936.HK	Air Freight & Logistics	32.3-36.3	200	N/A	2024/11/22	2024/11/26	2024/11/27
Jiuyuan Gene 02566.HK	Biotechnology - Medical Devices	11.48-12.56	200	N/A	2024/11/25	2024/11/27	2024/11/28
Mokingran 02585.HK	Watch & Jewellery	12-14.4	200	N/A	2024/11/26	2024/11/28	2024/11/29

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

S.F. Holding
06936.HK

Air Freight & Logistics

32.3-36.3

200

N/A

2024/11/22

2024/11/26

2024/11/27

Jiuyuan Gene
02566.HK

Biotechnology - Medical Devices

11.48-12.56

200

N/A

2024/11/25

2024/11/27

2024/11/28

Mokingran
02585.HK

Watch & Jewellery

12-14.4

200

N/A

2024/11/26

2024/11/28

2024/11/29

Summary

We are the largest provider in the Integrated Healthcare Marketing Solutions Market, which primarily include medical conference services, patient education and screening services and marketing strategy and consulting services, for cardio-cerebral-vascular diseases, or CCVDs, in China in terms of revenue in 2019, with a market share of 4.9% in the highly fragmented integrated healthcare marketing solutions industry for CCVDs, according to the CIC Report. The Integrated Healthcare Marketing Solutions Market for CCVDs in China was a RMB5.6 billion market in 2019, accounting for approximately 10.6% of the overall Integrated Healthcare Marketing Solutions Market in China. Founded in 2000, we primarily provide (i) medical conference services, (ii) patient education and screening services, and (iii) marketing strategy and consulting services with the goal to address the unmet needs of each key constituent of the CCVD healthcare ecosystem, including physicians, patients, pharmaceutical companies, medical non-governmental organizations, or NGOs, and hospitals, and to bridge the gaps among these constituents. In addition to providing integrated healthcare marketing solutions, we also began to offer CRO services in late 2019 which primarily consist of patients' recruitment and clinical data collection services, and internet hospital services which mainly provide online follow up consultation to the physicians' existing patients and e-prescription service. We focus on CCVDs though our disease coverage has been extended to other chronic diseases, such as diabetes and respiratory diseases. We have been committed to enabling better medical service and patient experience, improved disease control and lower the burden on the healthcare system in the long run through our services. We benefit from a high quality base of well-known customers and a physicians network, which have been crucial to our historical success. We have collaborated with some of China's most esteemed medical NGOs, including the only medical association for CCVDs recognized by the China Association for Science and Technology (中國科學技術協會), or CAST, which is the official organization for national professional societies in relation to science and technology in China. According to the CIC Report, among the global top ten pharmaceutical companies in terms of revenue in 2019, five were our customers during the Track Record Period. Moreover, we have developed a network of approximately 24,000 CCVD physicians as of June 30, 2020, among which over 70% worked for Grade 3 hospitals in China. All these physicians have participated in our provision of integrated healthcare marketing solutions. We have also established a medical advisory panel comprising four influential and well-recognized CCVD physicians to advise us on our strategic direction and business expansion, including the development of internet hospital services and CRO services. We have built various technology platforms to enhance our integrated healthcare marketing solutions. To strengthen our conference management capabilities, we have launched the Conference+ App (醫會+) for users, i.e. medical NGOs and pharmaceutical companies, to submit onsite conference requests and monitor conference implementation. We have also acquired Weiliandong, the owner of the Giraffe Platform which is a video conferencing and online education tool that enables hospitals to host or attend online medical conferences and access training videos recorded by physicians. To boost our patient education and screening capabilities, we developed and launched the Online Conference Assistant (線上會議助手), a WeChat mini-program that assists physicians in organizing and managing onsite patient education classes, as well as various WeChat public accounts where patients can find self-management support through watching educational videos, reading disease-related educational articles and conducting disease risk screening. We developed a mobile platform which offers online consultation and e-prescription services under our internet hospital segment as of the Latest Practicable Date. Source: Mediwelcome (02159) Prospectus (IPO Date : 2020/12/31)
Listing Market	MAIN
Industry	Health Care Services
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Shi Wei (21.63%) Yang Weimin (12.71%) Zhang Yitao (12.71%) The Core Trust Company Limited (10.00%) Wang Liang (7.22%)
Directors	Shi Wei (Chairman and Executive Director) Yang Weimin (Vice Chairman and Executive Director) Wang Liang (Chief Executive Officer and Executive Director) Liu Guijin (Executive Director) Liu Xia (Non-Executive Director) David Zheng Wang (Independent Non-Executive Director) Song Ruilin (Independent Non-Executive Director) Yang Xiaoxi (Independent Non-Executive Director)
Company Secretary	Zhao Luyang Tsoi Siu Wai
Principal Bankers	Bank of Communications Co., Ltd.
Solicitors	Sidley Austin
Auditors	Moore CPA Limited
Registered Office	Unit 1218, 12/F., Corporation Square, No.8 Lam Lok Street, Kowloon Bay, Kowloon, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.mediwelcome.com
Email Address	IR@mediwelcome.com
Tel No	(852) 2725-0298
Fax No	(852) 2802-0331

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates